Ricerc@Sapienza

Purpose: This study was directed to compare diagnostic accuracy of dual-phase cone beam computed tomography (DP-CBCT) vs pre-procedural second line imaging modality (SLIM [multidetector computed tomography and magnetic resonance imaging]) to detect and characterize hepatocellular carcinoma (HCC) in cirrhotic patients with indication for trans-arterial chemoembolization (TACE). Methods: This is a single centre, retrospective, and observational study. Exclusion criteria were not-assisted DP-CBCT TACE, and unavailable follow-up SLIM.

A large international study has been recently published focusing
on the combination of morphological aspects and alpha-fetoprotein
(AFP) as predictors of survival in patients with hepatocellular cancer
(HCC) treated with liver transplantation (LT) [1] . As a matter of
fact, morphology and biology represent the two sides of the same
coin, namely tumor aggressiveness. Several studies already investigated
the combinatory role of morphology and biology [2–4] .
The great merit of this study is that a “user-friendly” calculator

AIM: To perform a systematic review and meta-analysis on platelet-to-lymphocyte ratio (PLR) as a risk factor for post-transplant hepatocellular cancer (HCC) recurrence. METHODS: A systematic literature search was performed using PubMed. Participants of any age and sex, who underwent liver transplantation for HCC were considered following these criteria: (1) studies comparing pre-transplant low vs high PLR values; (2) studies reporting post-transplant recurrence rates; and (3) if more than one study was reported by the same institute, only the most recent was included.

Trans-arterial radio-embolization (TARE) with yttrium-90
represents one of the most efficacious approaches for the
treatment of selected patients with advanced hepatocellular
cancer (HCC) (1). Recent studies have confirmed the
superiority of TARE when compared with other intraarterial
treatments (2,3). A randomized phase II study
comparing TARE and trans-arterial chemo-embolization
(TACE) in HCC patients meeting Barcelona Clinic
Liver Cancer stages A-B showed a longer median timeto-